Whole body hyperthermia induction of soluble tumor necrosis factor receptors: Implications for rheumatoid diseases

被引:0
作者
Robins, HI
Grosen, E
Katschinski, DM
Longo, W
Tiggelaar, CL
Kutz, M
Winawer, J
Graziano, F
机构
[1] Univ Wisconsin, Ctr Comprehens Canc, Sch Med, Dept Med, Madison, WI 53792 USA
[2] Univ Wisconsin, Sch Med, Dept Obstet Gynecol, Madison, WI 53792 USA
[3] Univ Lubeck, Dept Physiol, D-2400 Lubeck, Germany
关键词
whole body hyperthermia; cytokines; tumor necrosis factor; soluble tumor necrosis factor receptors; interleukin; 10;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To test the hypothesis that 41.8 degrees C x 60 min whole body hyperthermia (WBH) induces increased serum levels of soluble necrosis factor receptors (sTNF-R). Methods. We tested the serum of cancer patients for changes in sTNF-RI and RII levels, as a function of time, pre and post: (1) WBH alone, (2) WBH and chemotherapy, i.e,, melphalan (L-PAM), and (3) L-PAM alone. Results. For sTNF-RI there was a marked increase (over pre-treatment values, i.e., 86%) in serum levels after WBH alone (n = 3), which peaked 2.5 h post-WBH; L-PAM (iv) only resulted in a dip in sTNF-RI seen 40 min postadministration; the combination (WBH + L-PAM), resulted in both the dip at 40 min and the increase at 2.5 h post-treatment. For sTNF-RII both WBH alone (n = 3) and WBH + L-PAM (n = 2), there was an increase in receptor serum levels of 25% and 30%, respectively, which peaked 5.5 h post-treatment, and remained elevated at 24 h. L-PAM alone resulted in a dip in levels only at 40 min post-treatment, sTNF-RI and RII levels returned to baseline values within 7 days post-treatment, Conclusion. 41,8 degrees C WBH results in transient increases in TNF-RI and RII. These results may have therapeutic implications for the application of WBH to TNF mediated disease processes.
引用
收藏
页码:2513 / 2516
页数:4
相关论文
共 50 条
  • [41] New tumor necrosis factor-alpha biologic therapies for rheumatoid arthritis
    Breedveld, F
    EUROPEAN CYTOKINE NETWORK, 1998, 9 (03) : 233 - 238
  • [42] How do tumor necrosis factor receptors work?
    Bazzoni, F
    Beutler, B
    JOURNAL OF INFLAMMATION, 1995, 45 (04) : 221 - 238
  • [43] Antimalarial drugs inhibit phospholipase A2 activation and induction of interleukin 1β and tumor necrosis factor α in macrophages:: Implications for their mode of action in rheumatoid arthritis
    Bondeson, J
    Sundler, R
    GENERAL PHARMACOLOGY, 1998, 30 (03): : 357 - 366
  • [44] CYTOKINE INDUCTION BY 41.8-DEGREES-C WHOLE-BODY HYPERTHERMIA
    ROBINS, HI
    KUTZ, M
    WIEDEMANN, GJ
    KATSCHINSKI, DM
    PAUL, D
    GROSEN, E
    TIGGELAAR, CL
    SPRIGGS, D
    GILLIS, W
    DOLEIRE, F
    CANCER LETTERS, 1995, 97 (02) : 195 - 201
  • [45] Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancer
    Gregorc, Vanesa
    Spreafico, Anna
    Floriani, Irene
    Colombo, Barbara
    Ludovini, Vienna
    Pistola, Lorenza
    Bellezza, Guido
    Vigano, Maria Grazia
    Villa, Eugenio
    Corti, Angelo
    CANCER, 2007, 110 (04) : 845 - 853
  • [46] Increased serum levels of soluble tumor necrosis factor a-receptors in patients undergoing partial liver resection
    Schroder, J
    Gallati, H
    Kremer, B
    HEPATO-GASTROENTEROLOGY, 1998, 45 (23) : 1807 - 1812
  • [47] High Levels of Soluble Tumor Necrosis Factor Receptors 1 and 2 and Their Association with Mortality in Patients Undergoing Hemodialysis
    Carlsson, Axel C.
    Carrero, Juan-Jesus
    Stenvinkel, Peter
    Bottai, Matteo
    Barany, Peter
    Larsson, Anders
    Arnlov, Johan
    CardioRenal Medicine, 2015, 5 (02) : 89 - 95
  • [48] Endogenous nitric oxide and soluble tumor necrosis factor receptor levels are enhanced in infants with congenital heart disease
    Buchhorn, R
    Wessel, A
    Hulpke-Wette, M
    Bürsch, J
    Werdan, K
    Loppnow, H
    CRITICAL CARE MEDICINE, 2001, 29 (11) : 2208 - 2210
  • [49] Tumor necrosis factor-A and kidney damage in rheumatoid arthritis
    Tsybulko, SV
    Baranov, AA
    Borodin, AG
    Korshunov, NL
    Kirdyanov, SY
    TERAPEVTICHESKII ARKHIV, 2001, 73 (05) : 8 - 11
  • [50] Rheumatoid arthritis: non-tumor necrosis factor targets
    Pollard, L
    Choy, E
    CURRENT OPINION IN RHEUMATOLOGY, 2005, 17 (03) : 242 - 246